A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.

Trial Details

NCT ID
NCT06225804
Phase
PHASE1
Sponsor
Abbisko Therapeutics Co, Ltd
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ABSK112
Locations (sample)
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Hefei, Anhui, China|31.86389,117.28083
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Xi'an, Harbin, China|34.25833,108.92861
  • Harbin, Heilongjiang, China|45.75,126.65

Key Eligibility Criteria

  • Patients should understand, sign, and date the written informed consent form prior to screening.
  • Male or female aged 18 years or older.
  • Patients with histologically or cytologically confirmed locally advanced (and not a candidate for definitive therapy) or metastatic NSCLC.
  • Cohort-specific inclusion criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →